The αMSH-Dependent PI3K Pathway Supports Energy Metabolism, via Glucose Uptake, in Melanoma Cells.
PI3K pathway
energy metabolism
glucose uptake
melanoma
αMSH
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
06 04 2023
06 04 2023
Historique:
received:
01
02
2023
revised:
29
03
2023
accepted:
04
04
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Stimulation of melanocytes and murine melanoma cells with αMSH plus the PI3K inhibitor LY294002 resulted in ROS increase, oxidative DNA damage, and pigment retention. We performed cellular and molecular biology assays (Western blot, FACS, immunofluorescence analysis, scratch assay) on murine and human melanoma cells. Treatment with αMSH plus LY294002 altered cortical actin architecture. Given that cytoskeleton integrity requires energy, we next evaluated ATP levels and we observed a drop in ATP after exposure to αMSH plus LY294002. To evaluate if the αMSH-activated PI3K pathway could modulate energy metabolism, we focused on glucose uptake by analyzing the expression of the Glut-1 glucose translocator. Compared with cells treated with αMSH alone, those exposed to combined treatment showed a reduction of Glut-1 on the plasma membrane. This metabolic alteration was associated with changes in mitochondrial mass. A significant decrease of the cell migratory potential was also observed. We demonstrated that the αMSH-dependent PI3K pathway acts as a regulator of energy metabolism via glucose uptake, influencing the actin cytoskeleton, which is involved in melanosome release and cell motility. Hence, these results could constitute the basis for innovative therapeutical strategies.
Identifiants
pubmed: 37048170
pii: cells12071099
doi: 10.3390/cells12071099
pmc: PMC10093374
pii:
doi:
Substances chimiques
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
alpha-MSH
581-05-5
Glucose
IY9XDZ35W2
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Mol Cell Biol. 2019 Jul;20(7):436-450
pubmed: 30976106
Cold Spring Harb Perspect Biol. 2012 Jul 01;4(7):a006783
pubmed: 22687276
Elife. 2021 Jan 13;10:
pubmed: 33438577
J Biol Chem. 1999 Jul 16;274(29):20281-6
pubmed: 10400647
J Immunol. 2008 Apr 1;180(7):4476-86
pubmed: 18354169
Nat Med. 2005 Sep;11(9):924-5
pubmed: 16145571
Biochim Biophys Acta Mol Basis Dis. 2017 Oct;1863(10 Pt A):2448-2461
pubmed: 28259754
Mol Cell Biol. 2003 Oct;23(20):7315-28
pubmed: 14517300
PPAR Res. 2017;2017:1830626
pubmed: 28529521
Oncol Lett. 2012 Dec;4(6):1151-1157
pubmed: 23226794
Annu Rev Pathol. 2020 Jan 24;15:235-259
pubmed: 31585519
Expert Rev Mol Diagn. 2022 Apr;22(4):439-447
pubmed: 35395916
Oncogene. 2018 Jul;37(27):3631-3646
pubmed: 29622793
Neuroendocrinology. 2017;104(4):330-346
pubmed: 27728914
Int J Mol Sci. 2018 Sep 08;19(9):
pubmed: 30205559
Oncotarget. 2015 Oct 20;6(32):32748-60
pubmed: 26293674
Pigment Cell Melanoma Res. 2015 Jul;28(4):378-89
pubmed: 25786343
Endocrinology. 2000 Sep;141(9):3072-9
pubmed: 10965876
Cell Metab. 2022 Mar 1;34(3):355-377
pubmed: 35123658
Pigment Cell Melanoma Res. 2018 Jan;31(1):11-30
pubmed: 29049843
Exp Mol Pathol. 2022 Aug;127:104787
pubmed: 35644245
Blood. 2008 Feb 15;111(4):2101-11
pubmed: 18042802
Mol Metab. 2016 Aug 05;5(10):807-822
pubmed: 27688995
Front Genet. 2016 May 31;7:95
pubmed: 27303435
Pigment Cell Res. 2000 Apr;13(2):60-9
pubmed: 10841026
Mol Biol Rep. 2020 Jun;47(6):4587-4629
pubmed: 32333246
FEBS Lett. 2021 Apr;595(8):1184-1204
pubmed: 33742459
Pigment Cell Melanoma Res. 2021 Mar;34(2):222-235
pubmed: 32997883
Pigment Cell Melanoma Res. 2021 Jul;34(4):748-761
pubmed: 33884776
J Exp Clin Cancer Res. 2017 Oct 11;36(1):142
pubmed: 29020973
Biomaterials. 2014 Feb;35(5):1597-607
pubmed: 24290441
Mol Med Rep. 2015 Mar;11(3):1573-81
pubmed: 25376370
Pancreas. 2008 Nov;37(4):426-31
pubmed: 18953257
Treat Endocrinol. 2006;5(1):7-13
pubmed: 16396514
Biochem Biophys Res Commun. 2014 Jan 10;443(2):447-52
pubmed: 24316214
Oncotarget. 2017 May 16;8(20):32946-32959
pubmed: 28380427
Biochim Biophys Acta. 2011 Aug;1812(8):1007-22
pubmed: 21382489
J Cell Sci. 2021 Feb 8;134(3):
pubmed: 33558441
Pigment Cell Melanoma Res. 2021 Jan;34(1):72-88
pubmed: 32608114
Curr Opin Oncol. 2012 Nov;24(6):650-4
pubmed: 22913968
Pigment Cell Melanoma Res. 2014 Sep;27(5):699-720
pubmed: 24807163
J Cell Sci. 1999 Mar;112 ( Pt 5):623-30
pubmed: 9973597
Cell Cycle. 2011 Jan 1;10(1):8-9
pubmed: 21200135
J Invest Dermatol. 1998 Nov;111(5):835-40
pubmed: 9804347
Mol Cell. 2013 Aug 22;51(4):409-22
pubmed: 23973372
Cells. 2018 Dec 27;8(1):
pubmed: 30591661
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
Br J Cancer. 2015 Jul 14;113(2):354-63
pubmed: 26103569
Oncotarget. 2016 Jul 12;7(28):43295-43314
pubmed: 27175588
Mol Biol Cell. 2007 Apr;18(4):1437-46
pubmed: 17301289
Pigment Cell Melanoma Res. 2013 Jan;26(1):113-27
pubmed: 22863076
Cells. 2021 Nov 09;10(11):
pubmed: 34831313
Mol Cell Biochem. 2018 Mar;440(1-2):127-138
pubmed: 28852964
Cancer Res. 2005 May 15;65(10):4292-9
pubmed: 15899821